| Kevin Michael Hewitt, MD | |
|
295 Varnum Ave, Lowell, MA 01854-2134 | |
| (978) 937-6000 | |
| Not Available |
| Full Name | Kevin Michael Hewitt |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 8 Years |
| Location | 295 Varnum Ave, Lowell, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699125328 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085D0003X | Radiology - Diagnostic Neuroimaging | 286707 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lowell General Hospital | Lowell, MA | Hospital |
| Melrosewakefield Healthcare | Melrose, MA | Hospital |
| Tufts Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Merrimack Radiology-cra Llc | 8426287269 | 55 |
| Mw Radiology-cra Llc | 6406270040 | 43 |
| Tmc Radiology Cra Llc | 4486041746 | 44 |
News Archive
Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.
Having a yearly mammogram greatly reduces the risk of mastectomy following breast cancer in women between the ages of 40 and 50, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.
› Verified 4 days ago
| Entity Name | Pratt Radiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154361780 PECOS PAC ID: 8820989411 Enrollment ID: O20040521000110 |
News Archive
Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.
Having a yearly mammogram greatly reduces the risk of mastectomy following breast cancer in women between the ages of 40 and 50, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.
› Verified 4 days ago
| Entity Name | Merrimack Radiology-cra Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275871154 PECOS PAC ID: 8426287269 Enrollment ID: O20140128000095 |
News Archive
Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.
Having a yearly mammogram greatly reduces the risk of mastectomy following breast cancer in women between the ages of 40 and 50, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.
› Verified 4 days ago
| Entity Name | Mw Radiology-cra Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114555398 PECOS PAC ID: 6406270040 Enrollment ID: O20200716000148 |
News Archive
Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.
Having a yearly mammogram greatly reduces the risk of mastectomy following breast cancer in women between the ages of 40 and 50, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.
› Verified 4 days ago
| Entity Name | Tmc Radiology Cra Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851046726 PECOS PAC ID: 4486041746 Enrollment ID: O20220505000580 |
News Archive
Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.
Having a yearly mammogram greatly reduces the risk of mastectomy following breast cancer in women between the ages of 40 and 50, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Michael Hewitt, MD 2 Clifton Park, Melrose, MA 02176-1111 Ph: (603) 370-0600 | Kevin Michael Hewitt, MD 295 Varnum Ave, Lowell, MA 01854-2134 Ph: (978) 937-6000 |
News Archive
Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.
Having a yearly mammogram greatly reduces the risk of mastectomy following breast cancer in women between the ages of 40 and 50, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.
› Verified 4 days ago
Michael Mastromatteo, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 295 Varnum Ave, Lowell, MA 01854 Phone: 978-741-1200 | |
Patrick Hanks, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 295 Varnum Ave, Lowell, MA 01854 Phone: 978-937-6000 | |
Scott D Abel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 295 Varnum Ave, Lowell, MA 01854 Phone: 978-937-6699 | |
Wei Du, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 295 Varnum Ave, Lowell, MA 01854 Phone: 978-937-6000 | |
Dr. Mark Elon Gale, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 295 Varnum Ave, Department Of Radiology, Lowell General Hospital, Lowell, MA 01854 Phone: 978-937-6240 | |
Jonas J Berman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 295 Varnum Ave, Lowell, MA 01854 Phone: 978-937-6000 | |
Klas D Romberg, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 155 Mansur St, Radiology Department, Lowell, MA 01852 Phone: 978-458-1851 |